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Abstract
Screening for diabetic retinopathy can help to prevent this complication, but evidence regarding frequency of screening is
uncertain. This paper systematically reviews the published literature on the relationship between screening intervals for
diabetic retinopathy and the incidence of visual loss. The PubMed and EMBASE databases were searched until
December 2012. Twenty five studies fulfilled the inclusion criteria, as these assessed the incidence/prevalence of
sight-threatening diabetic retinopathy in relation to screening frequency. The included studies comprised 15 evaluations
of real-world screening programmes, three studies modelling the natural history of diabetic retinopathy and seven
cost-effectiveness studies. In evaluations of diabetic retinopathy screening programmes, the appropriate screening
interval ranged from one to four years, in people with no retinopathy at baseline. Despite study heterogeneity, the overall
tendency observed in these programmes was that 2-year screening intervals among people with no diabetic retinopathy
at diagnosis were not associated with high incidence of sight-threatening diabetic retinopathy. The modelling studies
(non-economic and economic) assessed a range of screening intervals (1–5 years). The aggregated evidence from both the
natural history and cost-effectiveness models favors a screening interval >1 year, but ≤2 years. Such an interval would be
appropriate, safe and cost-effective for people with no diabetic retinopathy at diagnosis, while screening intervals
≤1 year would be preferable for people with pre-existing diabetic retinopathy. A 2-year screening interval for people
with no sight threatening diabetic retinopathy at diagnosis may be safely adopted. For patients with pre-existing diabetic
retinopathy, a shorter interval ≤1 year is warranted.
Diabet. Med. 30, 1272–1292 (2013)
Introduction
Diabetic retinopathy commonly complicates diabetes mell-
itus [1] and meets the World Health Organization (WHO)
criteria of suitability for screening [2]. It is a major cause
of vision loss worldwide. Approximately one third of
people with diabetes have diabetic retinopathy, and a third
of those with diabetic retinopathy may have sight-threat-
ening diabetic retinopathy, defined as clinically significant
proliferative retinopathy or macula oedema [1]. The
prevalence of diabetic retinopathy is projected to increase
in the coming decades. The number of Americans aged
40 years or older, for example, with diabetic retinopathy
and sight-threatening diabetic retinopathy is predicted to
triple by 2050 [3]. In China, the prevalence of diabetic
retinopathy among people with diabetes reaches 43% [1],
with up to 9.2 million people in rural areas having diabetic
retinopathy, including 1.3 million with sight-threatening
diabetic retinopathy [1].
The natural history of diabetic retinopathy is relatively
well understood, with recognizable stages. Major risk factors
for developing diabetic retinopathy include duration of
diabetes [4,5], severity of hyperglycaemia [6–8], hyperten-
sion [9] and dyslipidaemia [10]. Once sight-threatening
diabetic retinopathy is present, the progression is rapid and
complications are unpredictable. Twenty years after diagno-
sis, almost all people with Type 1 diabetes mellitus and 60%
of people with Type 2 diabetes mellitus will have some
degree of diabetic retinopathy [4,5].
There are precise, safe and accepted screening tests (oph-
thalmoscopy and fundus photography) for diabetic retinopa-
thy [11]. Glycaemic and blood pressure control may prevent
the progression of diabetic retinopathy [7,9]. Appropriately
timed laser photocoagulation therapy and, to a certain extent,Correspondence to: Justin B. Echouffo-Tcheugui. E-mail: jechouf@emory.edu
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anti-vascular endothelial growth factor (VEGF), can dramat-
ically reduce progression of sight-threatening diabetic reti-
nopathy to vision loss [12]. However, large numbers of
eligible patients requiring these preventive therapies may not
actually be receiving them. In the USA, up to 60% of patients
requiring vision-preserving laser surgery may not be receiving
optimally timed retinal photocoagulation [13].
Several national agencies recommend annual screening and
early treatment for sight-threatening diabetic retinopathy
lesions [14–16]. However, given the increasing demand for
ophthalmology services and costs associated with ophthalmic
care, an optimal screening interval has been debated, with
some suggesting the adoption of longer intervals for patients
with no background retinopathy, with more frequent sur-
veillance examinations for those at high risk [17–19]. Indeed,
there is accumulating evidence that the natural history of
diabetic retinopathy is sufficiently slow that 2-yearly retinal
screening, or even longer, may be safe for some patients with
diabetes [20], especially as information technology under-
pinning call–recall systems within screening programmes is
such that a more effective approach to organizing retinal
screening could allow moving towards a biennial retinal
screening programme. Consequently, screening low-risk
individuals too frequently implies an inefficient use of limited
healthcare resources.
Here, we systematically review the evidence regarding the
effect of screening intervals for diabetic retinopathy on the
incidence of sight-threatening diabetic retinopathy/visual
loss, and attempt to synthesize the available data in order
to guide the design of appropriate policy recommendations.
Methods
Data sources
We searched the PubMed and EMBASE electronic databases
for articles published until December 2012. We used a
combination of terms related to screening for diabetic
retinopathy (see also Supporting Information, Appendix S1).
Titles, abstracts and/or full texts of articles identified through
these searches were sequentially screened for inclusion (Fig. 1)
and electronic searches were supplemented by scanning the
references lists of relevant publications. When published data
were unclear, we contacted authors for further information.
Inclusion and exclusion criteria
Studies were included if they:
1. assessed a real-world diabetic retinopathy screening
programme and reported the incidence of sight threatening
retinopathy or blindness in relation to the screening
interval;
2. modelled the effect of varying screening interval for
diabetic retinopathy on the costs and/or cost-effectiveness
of diabetic retinopathy screening; or
3. modelled the effect of varying screening interval for
diabetic retinopathy on the incidence of sight-threatening
diabetic retinopathy or blindness.
Data extraction and quality assessment
Two reviewers (JBE-T and MKA) extracted relevant data,
including characteristics of the study population, study
setting, screening modalities, screening frequency, incidence
of sight-threatening diabetic retinopathy or blindness, and
measures of efficiency of the screening interval. Disagree-
ments were resolved by a third reviewer (KMN). To our
knowledge, there is no commonly agreed-upon unifying
framework to evaluate screening programmes and/or studies
of the natural history of diabetic retinopathy; we therefore
focus on the individual characteristics of each study, giving
more credit to well-designed, large, prospective studies with
appropriate measures of outcomes. Although not originally
designed for use in review articles, the Drummond and
Jefferson evaluation scheme [21] for evaluating the quality
of economic studies appeared to be a consensual tool
that has been previously used [22]; we therefore used it for
economic studies (see also Supporting Information,
Appendix S2).
Results
Of the 25 studies included in this review (Fig. 1), 15 could be
characterized as evaluations of actual screening programmes
[17,19,23–34], three as studies modelling the natural history
of the disease [35–37], seven were economic modelling
studies that explored screening interval (five cost-effective-
ness studies [38–42], one a cost-utility study [18] and one
combined cost-effectiveness and cost-utility analyses [43]).
Screening studies
Screening programme evaluations examined the relationship
between sight-threatening diabetic retinopathy occurrence
and the frequency of screening (Table 1), either as a primary
[17,27–30,32] or a secondary objective [19,23–26,31,33,
34,44]. None of these studies were conducted in regions
other than the USA, Europe and Australia. Four studies were
hospital-based [23,24,28,30] and the remainder were popu-
lation-based. Their sample size varied from 185 to 57 199.
Six of these studies exclusively recruited Caucasians [19, 23–
26, 32] and seven included non-white participants [17,27,
29,31,33,34,44], but had a majority of Caucasians. In two
studies, the ethnicity of participants was not clearly reported,
but given the setting of these studies it was logical to infer
that the vast majority of their participants were Caucasians
[28,30]. When clearly reported, the age of participants
ranged from 15 to 99 years. One study focused on children
and adolescents exclusively [28]. The average duration of
ª 2013 The Authors.
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diabetes at first screening varied between 0 and 15 years.
Thirteen of the 15 studies were retrospective cohorts and two
were prospective cohorts. One study reported using ophthal-
moscopy alone to ascertain diabetic retinopathy [23], fundal
photography alone was used in nine studies [25,27–30,32–
34,44], and a combination of ophthalmoscopy and fundal
photography was used in four studies [19,24,26,31].
The vast majority of the 15 screening studies addressed
screening for diabetic retinopathy in Type 1 and Type 2
diabetes together [19,23–26,29–31,44]. The screening stud-
ies provide unique information based on actual risk among
screened individuals, the majority of whom were not
receiving ophthalmic care. The appropriate screening inter-
val was variable, ranging from 1 year [44] to 4 years [30] in
people with no diabetic retinopathy at baseline. Despite the
between-studies variation, the overall tendency observed was
that a screening interval > 1 year would be appropriate and
safe in people with no diabetic retinopathy at diagnosis,
based on the extremely low rate of patients advancing from
no diabetic retinopathy to sight-threatening diabetic retinop-
athy in less than 2–3 years. Twelve of the 15 studies
supported a diabetic retinopathy screening interval > 1 year
[17,19,24,26–29,31–34,44]. The reported screening compli-
ance rate varied from 21% [27] to 28% [26].
A single study assessed the appropriate surveillance
intervals for those with diabetic retinopathy at diagnosis,
showing that a 1-year screening interval in the case of
background retinopathy and 0.3 of a year for mild prolif-
erative diabetic retinopathy, respectively, would be associ-
ated with a 95% probability of remaining free of
sight-threatening diabetic retinopathy for patients with
Type 2 diabetes [17]. Corresponding figures for Type 1
diabetes were 1.3 of a year for background and 0.4 of a year
for pre-proliferative diabetic retinopathy [27]. These were
the only studies that assessed the appropriate surveillance
intervals for those with diabetic retinopathy at diagnosis
[17,27]. Their findings are consistent with current consensus
in the medical community that yearly or more frequent
screening for people with any sign of diabetic retinopathy
should be the norm [12].
Some of the screening studies supporting an interval
> 1 year (e.g. a 2-year interval) included large-sample-size,
population-based cohorts with extended follow-up and/or
were specifically designed to assess the relationship between
screening interval and incidence of sight-threatening diabetic
retinopathy or blindness [17,27,29,33,34], thus offering
more robust evidence on the frequency of screening for
diabetic retinopathy. However, other studies putting forward
4886 citations identified essentially through PubMed 
(n = 1905) and EMBASE (n = 2981) and screened for 
identification of potentially relevant studies 
4819 articles excluded—960 duplicates and 3859 articles on the 
basis of the titles and/or abstracts not fulfilling the inclusion 
criteria 
67 studies retrieved for a more detailed evaluation  
25 studies included in the review  
15 screening studies  
3 studied modelling natural history  
7 economic modelling studies  
42 studies excluded as, on close reading of the full text, these did not 
provide clear information on the impact of screening intervals on health 
outcomes (incidence/prevalence of retinopathy) or costs  
FIGURE 1 Flow of selection of studies for inclusion.
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similar recommendations were relatively small in size,
[19,23,24,26,28,30,31] or were hospital based [28,30].
Studies supporting annual screening were not always specif-
ically designed to examine the relationship between less
frequent screening intervals and incidence of sight-
threatening diabetic retinopathy or blindness [25,44]. Fur-
thermore, the largest of these studies used the proportion of
blindness attributable to diabetic retinopathy as the main
outcome and information about blindness was obtained from
a registry [44].
In brief, the vast majority of evaluations of real-world
diabetic retinopathy screening programmes supported a
screening interval > 1 year.
Modelling studies
Natural history models
Modelling studies of the natural history are shown in
Table 2. A brief summary of the key specificities of each of
these studies are presented below.
Using a hypothetical population and a range of sensitivities
and specificities, to compare annual or biennial screening
until background diabetic retinopathy develops and then
examination 6 monthly or more frequently, Davies et al.
found that biennial screening is a safe and efficient strategy,
provided that patients’ compliance and screening sensitivities
are both high [35]. The net benefit of reducing the screening
interval for those with no diabetic retinopathy from 2 years
to 1 year would range from 0.25–0.42 years of sight saved
per person, depending on screening methods used or the
screener (ophthalmologist, general practitioner or optome-
trist).
Two Taiwan-based studies used data from real-world
screening programmes to derive the appropriate screening
interval for diabetic retinopathy [36,37]. None of these
models included the pathway to blindness through macul-
opathy.
Tung et al. advocated annual screening on the basis of the
incidence of blindness reduction for various screening regi-
mens: annual 94.4%; biennial 83.9%; 3-year 70.2%; 4-year
57.2%; 5-year 45.6% [36]. The best level of retinopathy in
each of the two eyes was used for patients with asymmetric
levels of severity; a sensitivity analysis choosing the worst eye
was conducted and found that estimates of the efficacy for
annual screening, biennial screening and 4-yearly screening
regimes were reduced to 40, 37 and 34%, respectively.
Although the absolute benefit diminished, the differences in
benefits with annual screening and biennial screening against
4-yearly screening were not substantial. The study of Tung
et al. [36] did not comprehensively describe the screening
intervals/strategies and made no clear distinction between
screening and surveillance once diabetic retinopathy is
detected. Thus, the length of the surveillance once diabetic
retinopathy is diagnosed was unclear. Screening was started
6 years after the diagnosis of diabetes; this delay may have
led to a higher number of people with advanced stages of
retinopathy when first seen. In addition, the average transi-
tion time from the mildest form of diabetic retinopathy to
proliferative retinopathy in Tung et al.’s study was
10.8 years [36]. Thus, a 2-year screening interval in people
with no diabetic retinopathy would still be less than one fifth
of this interval.
Liu et al. advocated biennial screening after finding that
annual screening, biennial screening and a 4-yearly screening
regime can lead to 54, 51 and 46% reductions in blindness,
respectively [37]. They used data from an ophthalmic care
centre where patients may have had better care and poten-
tially a lower rate of diabetic retinopathy progression.
However, they accounted for the levels of compliance and
metabolic control, making their model more close to reality.
They chose the best level of retinopathy in each of the two
eyes from all patients with asymmetric levels of severity; this
may raise concern as to whether this can affect the optimal
interval for screening patients with non-proliferative diabetic
retinopathy. Nonetheless, a sensitivity analysis choosing the
worst eye found that differences in benefits with annual
screening and biennial screening against 4-yearly screening
were not substantial.
Economic studies
Economic modelling studies evaluated the cost-effectiveness
or cost-utility of various screening intervals (Table 3). Two
studies addressed screening for diabetic retinopathy in
Type 1 and Type 2 diabetes [39,41] and five addressed
screening for Type 2 diabetes only [18,38,40,42,43]. As
indicated in Table 3 and in the Supporting Information
(Appendix S2), economic studies generally followed the key
steps of economic modeling, with a good description of the
model or simulation, along with source of data, costs and
outcome measures. The vast majority of these studies
favoured a screening interval > 1 year for people without
diabetic retinopathy at baseline. Given the heterogeneity of
assumptions used to conduct these studies, we summarize the
key aspects of individual studies below.
Dasbach et al. [41] examined three cohorts of incident
cases of diabetes, using two time horizons (10 and 60 years),
and concluded that annual screening would be better than
biennial screening. The 60-year net benefit conferred by an
annual compared with a biennial programme would be
28–36 years of sight saved for 1000 younger-onset patients,
7–9 years for 1000 older insulin-using patients and
3–4 years for 1000 older patients not using insulin. Over a
10-year time horizon, for the young patient cohort taking
insulin, the incremental cost-effectiveness ratio was
£2351.38–2554.55 ($3553–3860) per sight year saved for
1-year screening and £2522.78–2624.7 ($3812–3966) for
2-year screening. However, outcomes did not include mac-
ular oedema or values for non-discounted sight years, and
were unclear as to whether the rates of disease progression
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and death were derived from the study cohort or not. The
major inputs of disease progression and mortality were not
varied, which is potentially inadequate.
Javitt et al. [38] found that changing screening frequency
from 1 year to 2 years would have no detrimental effects on
years of sight saved, while demonstrating positive effects of
reducing the costs for patients with no or mild retinopathy.
Screening and treatment for diabetic retinopathy saved
£164.13 ($248) annually and 53 986 person-years of sight
in total. Nevertheless, for those with moderate non-prolifer-
ative or more advanced retinopathy, 8960 extra years of
sight would be saved by a 1-year programme over the
lifetime of the cohort ucode>—equating to 15.6 years per
1000 patients This model did not provide clear information
on the exact figures for sight saved by different screening
intervals for those with no baseline retinopathy, or include
sensitivity analysis for different intervals. Their methods for
determining annual and cohort cost and sight savings are not
clearly stated and benefits are from treatments for all types of
diabetic retinopathy.
Vijan et al. [18] showed that annual screening is more
effective; however, for most patients, the costs of annual
screening are considerable, with little marginal benefit when
compared with screening every other or every third year. The
marginal cost-effectiveness ratio of 1-year screening vs.
2-year screening was £71150.12 ($107 510/)quality-adjusted
life year gained, 2-year screening vs. 3-year was £32931.17
($49 760/) quality-adjusted life year gained; 3-year screening
vs. 5-year screening was £19959.89 ($30 160/) quality-ad-
justed life year gained. The cost-effectiveness ratio was
highest for patients whose onset of Type 2 diabetes occurred
at a younger age and whose glycaemic control is poor. Vijan
et al. addressed the limitations of a single perspective,
through an examination of the government or society
perspectives in a sensitivity analysis, and recommended a
2-year screening interval, with the option of tailoring the
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screening approach to the individual, so that those with the
poorest glycaemic control would be screened more often. An
alternate and safer option would be annual screening for all
patients, but offering 2- or 3-year screening to those with
good glycaemic control and with no retinopathy at baseline
was considered appropriate. Vijan et al. [18] did not provide
a basis for their choice of utility value (0.69) for blindness
and lesser levels of visual impairment. The utility value for
blindness had the biggest impact on cost-effectiveness in the
sensitivity analysis, with annual screening appearing to be
cost-effective at 0.48. Other studies defined utility values
ranging from 0.60 to 0.86 (depending on severity of vision
loss) [22]. Also, the assumed compliance rate in the model
was 100%, which is unrealistic. The model overlooked
potential variations in retinopathy risk in minority popula-
tions in the USA as these groups were not represented in UK
Prospective Diabetes Study (UKPDS) (from which the input
estimates were derived) [7]. Furthermore, the real-world
accuracy for detection is probably lower than that modelled,
and the prevalence of diabetic retinopathy was derived from a
national US survey that included only a single photograph of
each eye (sensitivity for retinopathy, 60%), rather than the
criterion standard 7-field photography. Similarly, progression
of disease was inferred from clinical trials in which partici-
pants are not representative of the overall population [45,46].
Davies et al. [39] showed that screening less than once a
year would not be cost-effective. The best cost-effectiveness
ratio was for annual screening and 6-month follow-up after
the detection of background diabetic retinopathy, at a cost of
£449 200 per year with £2842 per sight year saved.
Screening intervals were found to be a key area of
uncertainty, with a trade-off between the intervals, screening
sensitivity and compliance. However, they found that
increasing surveillance intervals to annual intervals once
non-proliferative diabetic retinopathy was detected rendered
results on biennial screening (those with no diabetic retinop-
athy on previous examinations) robust to such real-world
fluctuations. A 2-year screening frequency, before the detec-
tion of any retinopathy, was associated with a 10%
reduction in sight years saved, and an 8% reduction in the
cost per sight year saved. Davies et al. [39] did not discount
for costs and benefits and the non-assessment of patient costs
or cost benefits of preventing blindness. They explored the
benefits of dividing patients into groups, based on HbA1c,
and recalling them at different intervals, but such an
approach may not be practical in an actual screening
programme. They also combined screening and surveillance
intervals, but sensitivity analysis found that biennial screen-
ing was cost-effective if surveillance increased to at least
annual once any form of diabetic retinopathy was detected
on screening.
Using an ethnically mixed population (adjusting for the
higher prevalence of diabetes in ethnic minorities), and
various sensitivities and specificities of several screening
methods conducted by different types of health personnel,
Brailsford et al. compared the minimum and maximum cost
for years of sight saved of various screening policies [47].
They indicated that, without financial constraints on a
healthcare system, screening using a gold standard technol-
ogy in a hospital setting every 6 months (maximum
cost-effectiveness ratio: £5000/year of sight saved) can be
delivered. In contrast, if saving the maximum number of
sight years per pound spent is the objective, screening people
aged 30–60 years every 30 months with a mobile camera
would be appropriate (minimum cost-effectiveness ratio:
£1259/year of sight saved). This suggests that a 30-month
screening interval for diabetic retinopathy can be adopted;
however, healthcare systems that can afford to pay more to
prevent more cases of blindness may well choose not to
adopt the described minimum cost-effectiveness scenario.
Brailsford et al. [47] did not consider compliance, an
important variable in relation to screening intervals.
In a Taiwan-based model, using information on disease
characteristics and costs data from a real-life commu-
nity-based screening programme, Tung et al. [43] found
that efficacy and utility decreased, while cost increased with
the length of the screening/surveillance interval. For exam-
ple, the costs per sight year saved were (in New Taiwan
dollars) £1871.17($NT84 311) for no screening, £465.36
($NT20 962) for 16 annual screening, £554.78 ($NT24
990) for biennial screening, £684.8 ($NT30 847) for 3-year
screening, £831.06 ($NT37 435) for 4-year screening and
£98.77 ($NT4449) for 5-year screening. The authors con-
cluded that the ideal screening frequency should be annual.
By using data from a real-life programme data, Tung et al.
[43] probably estimated the true benefit of diabetic retinop-
athy screening more closely than in other modelling studies.
However, the programme was relatively small (n = 725
patients), thus possibly not representative of patients with
Type 2 diabetes. Moreover, the analysis did not consider the
sensitivity and specificity of various diabetic retinopathy
screening tests, used a single perspective and did not factor
in the indirect costs other than those incurred for screening.
Duration of diabetes and the HbA1c level were also not
examined, which may influence the efficacy of screening at
different intervals. Unlike most models, they do not note
increasing surveillance intervals once diabetic retinopathy is
detected on screening.
In a US-based model, Rein et al. [42] compared three
screening modalities (annual screening using dilated oph-
thalmoscopy, annual digital photography screening and
biennial ophthalmoscopy screening) and concluded that
biennial eye evaluation was the most cost-effective treatment
option when the ability to detect other eye conditions
(age-related macular degeneration and glaucoma) was
included in the model. Telemedicine was most cost-effective
when other eye conditions were not considered or when
telemedicine was assumed to detect refractive error. Annual
eye evaluation recommendation was costly compared with
either treatment alternative.
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Discussion
Our review provides a comprehensive synthesis of the
available evidence on the appropriate screening interval for
diabetic retinopathy. Although the evidence reviewed is
heterogeneous in nature, the general trend suggests that a
screening interval > 1 year, but no longer than 2 years,
would be effective (associated with reduction in the incidence
of sight-threatening diabetic retinopathy/blindness), safe and
cost-effective for people without diabetic retinopathy at
diagnosis. However, in high-risk patients with no diabetic
retinopathy at diagnosis with poor control of glycaemia or
blood pressure, more frequent screening may be warranted.
Also, a surveillance interval of 1 year or less would be
preferable in people with any diabetic retinopathy on a
previous examination. These findings somewhat contrast
with the currently recommended 1-year screening interval for
diabetic retinopathy in most Western countries, which is
based on observations from early population-based cohort
studies [4,8,48,49]. However, these cohort studies mainly
reported progression to proliferative diabetic retinopathy,
clinically significant macular oedema or photocoagulation,
rather than on progression to sight-threatening diabetic
retinopathy. The idea of a 2-year screening interval among
people without diabetic retinopathy is gaining ground in
Western countries and professional organizations such as the
Scottish Intercollegiate Guidelines Network have advocated
such an interval [50].
To our knowledge, this review is the first attempt to assess
the full range of studies addressing the issue of an ‘optimal’
screening interval for diabetic retinopathy. A previous review
examined this question, but only focused on economic
studies [22]. Studies evaluating real-world screening pro-
grammes provide an additional basis for the derivation of
appropriate screening intervals. By combining information
from these programmes and modelling studies, this review
presents information about screening interval in accordance
with the natural history of diabetic retinopathy and indica-
tions about the economic implications of various intervals.
However, it is important to understand the limitations of
studies included in this review.
Screening programmes were mainly evaluated using a
retrospective cohort design, which somewhat limits their
validity. However, in a context where no randomized
controlled trial of diabetic retinopathy screening exists, and
given the challenges of conducting one, decision-making can
reasonably rely on the best available observational evidence,
preferably from prospective studies. Ideally, decision on
appropriate screening intervals would be based on a ran-
domized controlled trial that randomly allocates people to
differing frequencies of screening. Nonetheless, it is very
difficult to afford such an allocation in a single study; as this
would require an incredibly high number of participants to
detect the true impact of any one screening interval.
Alternatively, parallel trials can assess the efficacy of the
same screening modality employed at different intervals.
However, such an approach may be intrinsically confounded;
it would be difficult to know if any observed difference is
related to differences in screening frequency, or rather to
variations in the nature of programmes, the early treatment
for the condition across settings or the population charac-
teristics that bear on the ability of screening to reduce
outcomes rates.
The methods used in evaluations of screening programmes
(sample size, setting, lack of control for important potential
confounders, definition and classification of sight-threatening
diabetic retinopathy/blindness, ascertainment of the presence
of retinopathy, timing of measurements and average diabetes
duration at diagnosis) were variable, rendering comparisons
difficult; hence, the variations noted in recommended
screening intervals for patients without baseline retinopathy.
There was a potential for underestimation of sight-threaten-
ing diabetic retinopathy/blindness incidence in some, if not
all, screening studies. For example, the definition of macular
oedema used in some studies did not meet the standard of
clinically significant macular oedema [30]. Although oph-
thalmic imaging was the most commonly used screening tool
[17,19,24–32,44], none of the screening programmes actu-
ally performed the gold standard test for diabetic retinopathy
screening (mydriatic stereoscopic 7-field retinal photogra-
phy). Thus, sight-threatening diabetic retinopathy or blind-
ness frequency may have been biased, although this would be
expected to affect mild diabetic retinopathy much more than
detection of vision-threatening diabetic retinopathy. How-
ever, the potential for bias is limited, given that the sensitivity
of screening tools used is in the range of 70–90% [11].
Furthermore, using mydriatic 7-field retinal photography in
population-based screening programmes may be logistically
challenging.
Some of the screening studies were relatively small in size
[19,23,24,26,28,30,31], or were hospital based [28,30], with
a potential for selection bias that could limit the generaliz-
ability of their findings. Furthermore, the use of the propor-
tion of blindness (obtained from a registry) attributable to
diabetic retinopathy as the main outcome of a screening
evaluation may limit the findings, given that a blindness
registry may not adequately capture all people with diabetic
retinopathy, thus raising the question of the completeness of
information on the data on blindness and other states of
lower vision [44].
In screening programmes, non-response was reasonably
common [26,27]. If non-attenders had worse glycaemic
control, and therefore a higher rate of progression than
those who comply, the incidence of sight-threatening
diabetic retinopathy may have been biased, as estimates
are limited to those who attended follow-up screening
sessions.
The head-to-head comparison of modelling studies (both
non-economic and economic) is difficult, as these originated
from different countries, used different currencies and
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costing methodologies and are based on different clinical
practices. The limitations of economic studies mainly relates
to their various assumptions. Some of the models did not
include the pathway to blindness through maculopathy
[36,37,41], potentially underestimating the incidence of
sight-threatening diabetic retinopathy. Other potential
sources of bias from the models include not varying the
major inputs of disease progression and mortality [41], not
considering the sensitivity and specificity of various diabetic
retinopathy screening tests [41], using a single perspective
without any sensitivity analysis including other perspectives
[38–41,43], not factoring in the indirect costs other than
those incurred for screening (with a potential bias toward
the effectiveness of the programme) [43], not discounting
costs and/or consequences associated with differential tim-
ing [38,39], not specifying how costs were measured
[38,43], not measuring all the consequences [38], not
accounting for the duration of diabetes and the HbA1c
level (may influence the efficacy of screening at different
intervals) [38,41,43] and not accounting for the screening
compliance rate [40,43].
The vast majority of studies examined in this review were
conducted in populations of predominantly European
descent. Furthermore, some of the modelling studies includ-
ing a mixed population overlooked potential variations in
retinopathy risk in all the subgroups included [7], raising the
issue of the generalizability of the findings. The susceptibility
to diabetic retinopathy and rate of progression may be higher
in other ethnic groups (people of African, Hispanic or Native
American descent), given the frequency of diabetic retinop-
athy in these groups [1] and their genetic susceptibility
[12,51]. It may therefore be difficult to extrapolate the results
presented here to these groups. In addition, the screening
programmes were conducted in high-income countries,
where the systems are generally better suited to influence
progression of diabetes, than in low- and middle-income
countries.
Strengths and limitations of the review
The strengths of this review include the appraisal of the
totality of the evidence on screening interval for diabetic
retinopathy, especially that from real-world screening pro-
grammes, and thus its potential utility in helping to choose
the most appropriate screening interval in guidelines. How-
ever, any policy modification or adoption should be
followed by an extensive evaluation, especially in low- and
middle-income countries, as the vast majority of existing
studies have been conducted in the Western world. The
review is limited by the partial reliance on modelling studies
with their many assumptions, rather than real-life data.
Also, we ranked the quality of economic studies using a
scoring system; such a rating is not completely without
subjectivity. Finally, our ability to assess publication bias
was limited.
Conclusions
This review of evidence suggests that a 2-year screening
interval for people with diabetes and no diabetic retinopathy
at diagnosis may be safely adopted. However, this is
contingent upon the availability of facilities to conduct
appropriate eye examinations and deliver appropriate care to
people detected. Available data, especially from real-life
screening programmes, was mainly retrospective and origi-
nated from studies in Caucasians; additional prospective data
from non-Caucasian populations, especially in low- and
middle-income countries, are therefore needed. Such data
may confirm whether the suggested 2-year screening interval
is safe and sustainable in any population and/or any health
system. The choice of a screening interval should account for
the context; consideration should be given to capacity of the
health system to perform screening at the indicated frequency
and to provide appropriate treatment.
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